Lacosamide Stada

Lacosamide, the active ingredient in Lacosamide Stada, is a sodium channel modifier presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing antiepileptic regimens. The drug enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes.

GNH USA supplies Lacosamide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Its distribution complies with European Union quality standards and is intended for use in regulated healthcare settings.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: provides adjunctive seizure control when added to existing antiepileptic therapy in patients with epilepsy. - Focal seizures: helps reduce the frequency of focal seizure episodes as part of combination treatment. - Epilepsy with refractory partial seizures: offers an additional therapeutic option for patients whose seizures are not adequately controlled by other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: such as PR‑interval prolongation or atrioventricular block. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts or behavior: emergence of depressive symptoms or suicidal ideation.

When prescribing lacosamide, clinicians should consider several safety aspects.

- Renal impairment: adjust therapy and monitor renal function. - Hepatic impairment: use with caution and assess liver enzymes. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Pregnancy: safety not established; weigh benefits against potential risks. - Suicidal ideation: monitor patients for mood changes and depressive symptoms. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Lacosamide can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacosamide levels and efficacy. - Other sodium‑channel blockers (e.g., phenytoin, carbamazepine): increase risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Antihypertensive agents: additive blood pressure‑lowering effect. - Other antiepileptic drugs: may require dose adjustments based on therapeutic response.